Sanjivani Ayurveda in Vadodara Announces Root-Cause Ayurvedic Approach to Chronic Disease Management
'Ayurveda isn't alternative—it's the original science of healing. And we practice it as it was meant to be.'— Dr. Kuldeep, Founder of Sanjivani Ayurveda
VADODARA, GUJARAT, INDIA, August 6, 2025 / EINPresswire.com / -- In an era dominated by quick fixes and symptom-based treatment, Sanjivani Ayurveda stands out by embracing the ancient wisdom of root-cause healing through Ayurveda. Led by renowned Ayurvedic expert Dr. Kuldeep Patel, the clinic has become a trusted name for patients seeking authentic, side-effect-free solutions to some of the most complex health conditions.
What sets Sanjivani Ayurveda apart is its personalized and principle-based approach—treating the root imbalances rather than just the visible symptoms. From Gangrene and Liver Cirrhosis to Psoriasis, Rheumatoid Arthritis, PCOD, and digestive or autoimmune disorders, the clinic's patients are experiencing real, lasting relief—without steroids, surgery, or synthetic drugs.
'When hospitals gave up, Sanjivani gave us hope—and results. My mother's Gangrene was reversed. They truly saved her leg,'
— said a grateful family member of a Sanjivani patient.
Based in Vadodara, Gujarat, Sanjivani Ayurveda is built on the principle that every individual has a unique dosha (body constitution), and effective healing comes from treating that individual constitution with precision and care. Unlike many clinics offering generalized treatments, Dr. Patel crafts customized protocols for each patient after a detailed root-cause assessment.
While many patients arrive at the clinic as a 'last resort,' Sanjivani is working to flip that narrative—positioning Ayurveda as the first line of treatment, not the fallback.
From detoxifying the liver to managing chronic pain and restoring hormonal balance, Sanjivani's holistic approach is redefining recovery for hundreds across India. The treatments are natural, ethical, and deeply rooted in classical Ayurvedic texts—blended with modern diagnostic insights when needed.
Whether you are dealing with an autoimmune condition, skin disorder, lifestyle disease, or complex metabolic imbalance, Sanjivani offers you something rare: clarity, care, and cure without compromise.
Dr. Kuldeep Patel
Sanjivani Ayurveda
+91 88661 16666
[email protected]
Visit us on social media:
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Wegovy, Mounjaro sales in India double on month in July
By Rishika Sadam and Kashish Tandon HYDERABAD (Reuters) -Sales of Danish drugmaker Novo Nordisk's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month earlier, data from research firm Pharmarack showed on Thursday. Demand for the blockbuster anti-obesity drugs, which help control blood sugar and slow digestion, has been on an upswing in the world's most populous nation. Sales of Wegovy, launched locally in June, more than doubled to 5,000 units or 70 million rupees ($798,230) in July, the data showed. Mounjaro sales also doubled month-on-month to 157,000 units or 470 million rupees. "Though Wegovy has a strong prescriber base because of Rybelsus, substantial promotion may be needed to reach the Mounjaro patient base for the injectable market," Pharmarack's Vice President (Commercial) Sheetal Sapale said in a statement. In India, Novo has been selling oral semaglutide pills under the brand name Rybelsus since 2022 for type 2 diabetes. Mounjaro's sales have soared 15 times since March, when the drug was launched in India. ($1 = 87.6790 Indian rupees) Sign in to access your portfolio
Yahoo
8 hours ago
- Yahoo
This herb can improve brain function, slash stress, and even reduce inflammation
It's a herb with several names. Some know it as brahmi. Others call it water hyssop. It's also referred to as bacopa, or bacopa monnieri. But, many don't know 'the herb of grace' at all. Still, the perennial herb has been used for centuries in Indian Ayurveda traditional medicine, according to the Cleveland Clinic, and boasts brain boosting benefits, among others. 'Bacopa monniera protects the brain through antioxidants,' registered dietitian Sarah Thomsen Ferreira previously told the clinic. 'It helps to stimuli enzymes in our body's own antioxidant defense system.' Antioxidants include vitamins and minerals that prevent cell damage and are found in many foods. A diet high in antioxidants can help to reduce the risk of chronic disease. Bacopa's brain impacts haven't been studied in humans, but trials in animals have 'established a biological rationale for protective properties,' according to the Alzheimer's Drug Discovery Foundation. The small trials have made it challenging to draw firm conclusions, but a systematic review of the research reported at least one statistically significant improvement on at least one neuropsychological measure in the majority of trials it analyzed, the non-profit said. But, that's not the only reason you may want to use the tropical herb in your next cup of tea or protein shake -- after consulting with a doctor, of course. Bacopa is an adaptogen, the clinic notes. Adaptogens are groups of plants and herbs that can reduce stress. It is believed they work by interacting with the hypothalamic-pituitary-adrenal axis: a group of three endocrine system organs that initiate the body's stress response, according to UCLA Health. The organs include the brain's hypothalamus and pituitary gland and the kidneys' adrenal glands. All of the organs regulate hormones, which cause stress. Lastly, several studies have found that bacopa can reduce inflammation in the central nervous system and related pain. Inflammation, which is our immune system's natural response to invaders, can be harmful when it persists. Chronic inflammation has been linked to heart disease, respiratory illness, autoimmune disease, arthritis, dementia, cancer, and other conditions, according to the Cleveland Clinic. Bacopa is generally considered to be safe, but not all of its risks have been studied and may vary by individual. The foundation warns that some sources could be unsafe, depending on where the plant is grown. 'Consider choosing supplements whose content has been verified by a third party,' it said.
Entrepreneur
9 hours ago
- Entrepreneur
Thyrocare CEO Rahul Guha to Lead PharmEasy as Siddharth Shah Steps Down
Effective August 27, 2025, Shah will assume the position of Vice Chairman and Director at the parent company of PharmEasy and Thyrocare. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Siddharth Shah, Co-founder and current MD and CEO of API Holdings, is stepping down from his executive role later this month. Effective August 27, 2025, Shah will assume the position of Vice Chairman and Director at the parent company of PharmEasy and Thyrocare. Rahul Guha, presently the MD and CEO of Thyrocare, has been appointed as the new MD and CEO of API Holdings. The leadership change was disclosed in regulatory filings by Thyrocare on Wednesday. Guha will continue to oversee Thyrocare while taking on his new responsibilities at API Holdings. Guha brings significant experience to the role. Prior to his elevation, he served as President of Operations at API Holdings, where he led group-level integration and coordination efforts. PharmEasy had acquired a controlling 66.1 percent stake in Thyrocare in June 2021 for INR 4,546 crore. The leadership consolidation is seen as a strategic step by API Holdings to streamline operations amid ongoing financial challenges and long-term preparations for a potential public listing. API Holdings had earlier filed draft documents for an initial public offering in 2021 but withdrew due to unfavorable market conditions. The company has raised approximately USD 1.1 billion from investors such as MEMG, Prosus, and Temasek. In April 2024, it secured USD 216 million in funding at a significantly reduced valuation of USD 710 million. The transition follows the departure of PharmEasy's three cofounders earlier this year. The trio has since launched a new startup, All Home, which recently raised funding from Bessemer Venture Partners, valuing it at over USD 120 million. Shah has also invested in the venture.
